Global Gastrointestinal Drugs Market Growth (Status and Outlook) 2026-2032

Product Code: 2025760

Industry: Pharma & Healthcare

Published: Aug 16,2026

Pages: 147

Delivery Time: 2-3 business days

Global Gastrointestinal Drugs Market Growth (Status and Outlook) 2026-2032

Product Code: 2025760

Industry: Pharma & Healthcare

Published: Aug 16,2026

Pages: 147

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

The global Gastrointestinal Drugs market size is predicted to grow from US$ 81458 million in 2025 to US$ 118296 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Gastrointestinal Drugs refer to pharmaceutical products used for the prevention, symptom control, disease modification, and long-term management of disorders affecting the stomach, intestine, and related digestive functions. The market spans acid-related disorder drugs, inflammatory bowel disease drugs, irritable bowel syndrome drugs, constipation drugs, diarrhea drugs, gastrointestinal motility disorder drugs, and other gastrointestinal therapies. From a pharmacological perspective, the study covers acid suppressants, gastrointestinal anti-inflammatory drugs, immunomodulators and targeted therapies, gastrointestinal motility modulators, laxatives and intestinal secretagogues, antidiarrheal and intestinal anti-infective drugs, gastrointestinal mucosal protective drugs, and other mechanisms. Product forms include oral solid preparations, oral liquids and suspensions, injectable preparations, rectal preparations, and other formulations, while molecular modalities are divided into small molecule drugs and biologic drugs. The principal downstream channels covered by the study are hospitals, gastroenterology clinics, retail pharmacies, and online pharmacies, reflecting the combination of specialist-managed prescription treatment and long-term outpatient medication characteristic of the Gastrointestinal Drugs market.

Key Findings
Targeted biologics are reshaping advanced inflammatory bowel disease treatment
PCABs broaden mechanism choice in acid-related gastrointestinal therapy
Oral solid formulations remain central across chronic gastrointestinal treatment
Specialist channels anchor adoption of advanced gastrointestinal therapies
Small molecules and biologics create a dual-modality market structure
Market Trends
The Gastrointestinal Drugs market is evolving from broad symptom management toward more mechanism-specific, disease-modifying and patient-convenient therapies. In inflammatory bowel disease, therapeutic innovation has expanded beyond conventional anti-inflammatory and immunosuppressive approaches toward selective cytokine-targeted biologics and advanced oral therapies. Recent approvals involving IL-23 inhibitors and oral S1P-modulating therapies illustrate this diversification, while subcutaneous maintenance formulations are reducing dependence on infusion-based administration for some biologic treatments. In acid-related disorders, potassium-competitive acid blockers are adding a differentiated mechanism alongside established proton pump inhibition. Functional gastrointestinal disorders are also seeing continued innovation through intestinal secretagogues and locally acting or gut-focused small molecules. Together, these changes indicate that future competition will increasingly depend on mechanism differentiation, depth of clinical response, administration convenience, broader indication coverage, and the ability to support chronic treatment outside traditional hospital settings.

Market Dynamics
Drivers
Demand for Gastrointestinal Drugs is supported by the chronic and recurrent nature of many gastrointestinal conditions and by the continuing need to improve symptom control, mucosal healing, disease remission, and quality of life. More importantly, pharmaceutical innovation is expanding the treatable population by offering additional mechanisms for patients who respond inadequately to established therapies. The availability of targeted biologics, novel oral agents, newer acid-suppression mechanisms, and differentiated treatments for constipation and irritable bowel syndrome is increasing therapeutic choice and encouraging more individualized treatment pathways. Product lifecycle expansion through additional indications, age groups, and administration formats also supports sustained demand beyond initial product launch.

Restraints
The market is constrained by substantial differences in commercial economics between mature gastrointestinal medicines and innovative therapies. Established acid suppressants, motility agents, laxatives, and other long-standing small molecules are exposed to generic competition and price pressure, limiting differentiation based solely on formulation or mechanism. At the other end of the market, biologics and advanced targeted therapies require significant clinical-development investment, complex manufacturing and pharmacovigilance systems, and often face reimbursement and access restrictions. Safety monitoring requirements and treatment-selection complexity can further slow uptake of advanced agents, while the availability of multiple therapeutic alternatives increases the evidence required to demonstrate clinically meaningful differentiation.

Opportunities
The most attractive opportunities are shifting toward areas where existing treatment pathways still leave meaningful unmet need. In inflammatory bowel disease, opportunities remain in achieving deeper and more durable responses, expanding convenient subcutaneous or oral treatment options, and extending differentiated therapies across ulcerative colitis and Crohn’s disease. In acid-related disorders, newer mechanisms create room to address patients whose symptoms are not adequately controlled by established approaches. Functional bowel disorders provide another opportunity for mechanism-based oral therapies targeting constipation, diarrhea, secretion, motility, or intestinal transport. Lifecycle management through new indications, new age groups, optimized dosing, and more convenient formulations is also becoming an increasingly important source of product value.

Challenges
The principal challenge is maintaining clear clinical and commercial differentiation as the number of treatment mechanisms increases. This is especially relevant in inflammatory bowel disease, where biologics and advanced small molecules increasingly compete for overlapping patient populations and treatment lines. Manufacturers must demonstrate not only efficacy but also durability of response, acceptable safety, convenient administration, and practical advantages within real-world treatment pathways. For mature gastrointestinal categories, commoditization and generic substitution remain persistent pressures. Differences in reimbursement, prescribing practices, regulatory requirements, and access between countries also make global commercialization uneven, increasing the importance of region-specific evidence and market-access strategies.

Industry Chain Analysis
The Gastrointestinal Drugs industry chain begins with active pharmaceutical ingredients, biologic drug substances, excipients, formulation materials, delivery-device components where applicable, and pharmaceutical packaging. Midstream activities encompass drug discovery, preclinical and clinical development, formulation development, regulatory registration, API and finished-dose manufacturing, biologic production, fill-finish, quality control, and commercialization. The technical and capital intensity of this chain varies substantially by product type: conventional oral small molecules rely heavily on efficient synthesis, formulation, scale manufacturing and cost control, while targeted biologics require cell-culture or other biological production systems, more complex analytical control, cold-chain capabilities in many cases, and higher manufacturing-quality requirements.

Downstream value is realized through hospitals, gastroenterology clinics, retail pharmacies, and online pharmacies. Specialist medical institutions play the most important role in diagnosis, treatment initiation and monitoring of severe or complex diseases, particularly inflammatory bowel disease, while retail and online channels are increasingly relevant to repeat dispensing of chronic oral therapies. Across the chain, value creation is progressively shifting from simple drug availability toward therapeutic differentiation, clinical evidence, formulation convenience, reliable manufacturing, patient adherence support and market access. The resulting profitability structure therefore differs markedly between mature genericized gastrointestinal drugs and patent-protected, differentiated specialty therapies.

Segment Insights
By therapeutic area, the Gastrointestinal Drugs market contains both mature high-volume categories and innovation-intensive specialty segments. Acid-related disorder drugs have a broad clinical base and a well-established treatment pathway, but new acid-suppression mechanisms are creating additional differentiation within this mature field. Inflammatory bowel disease represents one of the most innovation-intensive segments because treatment is moving toward targeted biologics and advanced small molecules addressing specific immune pathways. Irritable bowel syndrome, constipation, diarrhea and gastrointestinal motility disorders remain predominantly oral-treatment markets, where differentiation increasingly depends on mechanism, symptom coverage, tolerability and treatment convenience.

From a dosage-form perspective, oral solid preparations retain the broadest applicability because they serve both common gastrointestinal conditions and an increasing number of specialty indications. Injectable preparations remain strategically important in biologic therapy, particularly for inflammatory bowel disease, although development of subcutaneous maintenance and self-administration options is gradually changing treatment delivery. From a molecular perspective, small molecule drugs continue to support broad outpatient use and mechanism diversity, while biologic drugs provide highly targeted approaches in immune-mediated gastrointestinal diseases. The coexistence of the two modalities is creating a market in which convenience and therapeutic specificity increasingly compete alongside traditional efficacy and safety considerations.

Downstream Market Opportunities
Hospitals and gastroenterology clinics remain central to the initiation and management of advanced Gastrointestinal Drugs because diagnosis, disease-severity assessment, biologic initiation, treatment switching and safety monitoring require specialist involvement. Retail pharmacies and online pharmacies are more relevant to recurring outpatient prescriptions, particularly oral acid suppressants, gastrointestinal motility drugs, constipation therapies and other chronic medications. The expansion of once-daily oral advanced treatments and subcutaneous self-administered formulations is gradually broadening the role of outpatient and home-based treatment, creating opportunities for products that reduce administration burden while maintaining long-term disease control.

Regional Insights
Regional development of the Gastrointestinal Drugs market is increasingly differentiated by regulatory access, reimbursement systems, specialist treatment infrastructure, and the speed at which novel mechanisms enter clinical practice. North America is an important launch and commercialization market for innovative gastrointestinal therapies, with recent regulatory activity spanning PCAB acid suppression, IL-23 biologics, oral advanced ulcerative colitis therapies, and expanded treatments for functional gastrointestinal disorders. Europe similarly supports adoption of advanced therapies but places greater emphasis on country-specific reimbursement and health-technology assessment, resulting in varying commercialization timelines after regulatory approval.

Asia represents a structurally important market for both established gastrointestinal medicines and newer mechanisms. Japan has been an early commercial market for potassium-competitive acid blockers, while China combines a large conventional gastrointestinal drug base with expanding demand for higher-value specialty treatment. Regional opportunity therefore does not depend on a single product category: mature markets are increasingly driven by therapeutic replacement and innovation, while developing markets retain additional potential from improving diagnosis, specialist treatment penetration, pharmaceutical access, and availability of differentiated therapies.

Report Scope
LPI (LP Information)' newest research report, the “Gastrointestinal Drugs Industry Forecast” looks at past sales and reviews total world Gastrointestinal Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Drugs sales for 2026 through 2032. With Gastrointestinal Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gastrointestinal Drugs industry.

This Insight Report provides a comprehensive analysis of the global Gastrointestinal Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Gastrointestinal Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gastrointestinal Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Gastrointestinal Drugs market by product type, application, key players and key regions and countries.

Market Segmentation
Segmentation by Type:
    Acid-Related Disorder Drugs
    Inflammatory Bowel Disease Drugs
    Irritable Bowel Syndrome Drugs
    Constipation Drugs
    Diarrhea Drugs
    Gastrointestinal Motility Disorder Drugs
    Other Gastrointestinal Drugs

Segmentation by Primary Dosage:
    Oral Solid Preparations
    Oral Liquid and Suspension Preparations
    Injectable Preparations
    Rectal Preparations
    Other Preparations

Segmentation by Drug Molecule:
    Small Molecule Drugs
    Biologic Drugs

Segmentation by Application:
    Inflammatory Bowel Disease
    IBS Disease
    Peptic Ulcer
    GERD
    Other

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    AstraZeneca
    Sanofi
    Bayer
    Pfizer
    GlaxoSmithKline
    Teva
    Ferring Pharmaceuticals
    Perrigo
    Boehringer Ingelheim
    Purdue Pharma
    Dr. Falk Pharma GmbH
    Abbott
    Jiangzhong
    Xian-Janssen
    Takeda Pharmaceutical
    AbbVie
    Eli Lilly and Company
    Johnson & Johnson
    Bristol Myers Squibb
    Bausch Health
    Livzon Pharmaceutical
    Shandong Luoxin Pharmaceutical
    Gilead Sciences
    Zhengdatianqing
    Zydus Lifesciences

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Gastrointestinal Drugs Market Size (2021-2032)
        2.1.2 Gastrointestinal Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)
        2.1.3 World Current & Future Analysis for Gastrointestinal Drugs by Country/Region (2021, 2025 & 2032)
    2.2 Gastrointestinal Drugs Segment by Type
        2.2.1 Acid-Related Disorder Drugs
        2.2.2 Inflammatory Bowel Disease Drugs
        2.2.3 Irritable Bowel Syndrome Drugs
        2.2.4 Constipation Drugs
        2.2.5 Diarrhea Drugs
        2.2.6 Gastrointestinal Motility Disorder Drugs
        2.2.7 Other Gastrointestinal Drugs
        2.2.8 Gastrointestinal Drugs Market Size by Type
            2.2.8.1 Gastrointestinal Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
            2.2.8.2 Global Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
    2.3 Gastrointestinal Drugs Segment by Primary Dosage
        2.3.1 Oral Solid Preparations
        2.3.2 Oral Liquid and Suspension Preparations
        2.3.3 Injectable Preparations
        2.3.4 Rectal Preparations
        2.3.5 Other Preparations
        2.3.6 Gastrointestinal Drugs Market Size by Primary Dosage
            2.3.6.1 Gastrointestinal Drugs Market Size CAGR by Primary Dosage (2021 VS 2025 VS 2032)
            2.3.6.2 Global Gastrointestinal Drugs Market Size Market Share by Primary Dosage (2021-2026)
    2.4 Gastrointestinal Drugs Segment by Drug Molecule
        2.4.1 Small Molecule Drugs
        2.4.2 Biologic Drugs
        2.4.3 Gastrointestinal Drugs Market Size by Drug Molecule
            2.4.3.1 Gastrointestinal Drugs Market Size CAGR by Drug Molecule (2021 VS 2025 VS 2032)
            2.4.3.2 Global Gastrointestinal Drugs Market Size Market Share by Drug Molecule (2021-2026)
    2.5 Gastrointestinal Drugs Segment by Application
        2.5.1 Inflammatory Bowel Disease
        2.5.2 IBS Disease
        2.5.3 Peptic Ulcer
        2.5.4 GERD
        2.5.5 Other
        2.5.6 Gastrointestinal Drugs Market Size by Application
            2.5.6.1 Gastrointestinal Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
            2.5.6.2 Global Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)

3 Gastrointestinal Drugs Market Size by Player
    3.1 Gastrointestinal Drugs Market Size Market Share by Player
        3.1.1 Global Gastrointestinal Drugs Revenue by Player (2021-2026)
        3.1.2 Global Gastrointestinal Drugs Revenue Market Share by Player (2021-2026)
    3.2 Global Gastrointestinal Drugs Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion

4 Gastrointestinal Drugs by Region
    4.1 Gastrointestinal Drugs Market Size by Region (2021-2026)
    4.2 Global Gastrointestinal Drugs Annual Revenue by Country/Region (2021-2026)
    4.3 Americas Gastrointestinal Drugs Market Size Growth (2021-2026)
    4.4 APAC Gastrointestinal Drugs Market Size Growth (2021-2026)
    4.5 Europe Gastrointestinal Drugs Market Size Growth (2021-2026)
    4.6 Middle East & Africa Gastrointestinal Drugs Market Size Growth (2021-2026)

5 Americas
    5.1 Americas Gastrointestinal Drugs Market Size by Country (2021-2026)
    5.2 Americas Gastrointestinal Drugs Market Size by Type (2021-2026)
    5.3 Americas Gastrointestinal Drugs Market Size by Application (2021-2026)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Gastrointestinal Drugs Market Size by Region (2021-2026)
    6.2 APAC Gastrointestinal Drugs Market Size by Type (2021-2026)
    6.3 APAC Gastrointestinal Drugs Market Size by Application (2021-2026)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia

7 Europe
    7.1 Europe Gastrointestinal Drugs Market Size by Country (2021-2026)
    7.2 Europe Gastrointestinal Drugs Market Size by Type (2021-2026)
    7.3 Europe Gastrointestinal Drugs Market Size by Application (2021-2026)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Gastrointestinal Drugs by Region (2021-2026)
    8.2 Middle East & Africa Gastrointestinal Drugs Market Size by Type (2021-2026)
    8.3 Middle East & Africa Gastrointestinal Drugs Market Size by Application (2021-2026)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Global Gastrointestinal Drugs Market Forecast
    10.1 Global Gastrointestinal Drugs Forecast by Region (2027-2032)
        10.1.1 Global Gastrointestinal Drugs Forecast by Region (2027-2032)
        10.1.2 Americas Gastrointestinal Drugs Forecast
        10.1.3 APAC Gastrointestinal Drugs Forecast
        10.1.4 Europe Gastrointestinal Drugs Forecast
        10.1.5 Middle East & Africa Gastrointestinal Drugs Forecast
    10.2 Americas Gastrointestinal Drugs Forecast by Country (2027-2032)
        10.2.1 United States Market Gastrointestinal Drugs Forecast
        10.2.2 Canada Market Gastrointestinal Drugs Forecast
        10.2.3 Mexico Market Gastrointestinal Drugs Forecast
        10.2.4 Brazil Market Gastrointestinal Drugs Forecast
    10.3 APAC Gastrointestinal Drugs Forecast by Region (2027-2032)
        10.3.1 China Gastrointestinal Drugs Market Forecast
        10.3.2 Japan Market Gastrointestinal Drugs Forecast
        10.3.3 Korea Market Gastrointestinal Drugs Forecast
        10.3.4 Southeast Asia Market Gastrointestinal Drugs Forecast
        10.3.5 India Market Gastrointestinal Drugs Forecast
        10.3.6 Australia Market Gastrointestinal Drugs Forecast
    10.4 Europe Gastrointestinal Drugs Forecast by Country (2027-2032)
        10.4.1 Germany Market Gastrointestinal Drugs Forecast
        10.4.2 France Market Gastrointestinal Drugs Forecast
        10.4.3 UK Market Gastrointestinal Drugs Forecast
        10.4.4 Italy Market Gastrointestinal Drugs Forecast
        10.4.5 Russia Market Gastrointestinal Drugs Forecast
    10.5 Middle East & Africa Gastrointestinal Drugs Forecast by Region (2027-2032)
        10.5.1 Egypt Market Gastrointestinal Drugs Forecast
        10.5.2 South Africa Market Gastrointestinal Drugs Forecast
        10.5.3 Israel Market Gastrointestinal Drugs Forecast
        10.5.4 Turkey Market Gastrointestinal Drugs Forecast
    10.6 Global Gastrointestinal Drugs Forecast by Type (2027-2032)
    10.7 Global Gastrointestinal Drugs Forecast by Application (2027-2032)
        10.7.1 GCC Countries Market Gastrointestinal Drugs Forecast

11 Key Players Analysis
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Information
        11.1.2 AstraZeneca Gastrointestinal Drugs Product Offered
        11.1.3 AstraZeneca Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.1.4 AstraZeneca Main Business Overview
        11.1.5 AstraZeneca Latest Developments
    11.2 Sanofi
        11.2.1 Sanofi Company Information
        11.2.2 Sanofi Gastrointestinal Drugs Product Offered
        11.2.3 Sanofi Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.2.4 Sanofi Main Business Overview
        11.2.5 Sanofi Latest Developments
    11.3 Bayer
        11.3.1 Bayer Company Information
        11.3.2 Bayer Gastrointestinal Drugs Product Offered
        11.3.3 Bayer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.3.4 Bayer Main Business Overview
        11.3.5 Bayer Latest Developments
    11.4 Pfizer
        11.4.1 Pfizer Company Information
        11.4.2 Pfizer Gastrointestinal Drugs Product Offered
        11.4.3 Pfizer Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.4.4 Pfizer Main Business Overview
        11.4.5 Pfizer Latest Developments
    11.5 GlaxoSmithKline
        11.5.1 GlaxoSmithKline Company Information
        11.5.2 GlaxoSmithKline Gastrointestinal Drugs Product Offered
        11.5.3 GlaxoSmithKline Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.5.4 GlaxoSmithKline Main Business Overview
        11.5.5 GlaxoSmithKline Latest Developments
    11.6 Teva
        11.6.1 Teva Company Information
        11.6.2 Teva Gastrointestinal Drugs Product Offered
        11.6.3 Teva Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.6.4 Teva Main Business Overview
        11.6.5 Teva Latest Developments
    11.7 Ferring Pharmaceuticals
        11.7.1 Ferring Pharmaceuticals Company Information
        11.7.2 Ferring Pharmaceuticals Gastrointestinal Drugs Product Offered
        11.7.3 Ferring Pharmaceuticals Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.7.4 Ferring Pharmaceuticals Main Business Overview
        11.7.5 Ferring Pharmaceuticals Latest Developments
    11.8 Perrigo
        11.8.1 Perrigo Company Information
        11.8.2 Perrigo Gastrointestinal Drugs Product Offered
        11.8.3 Perrigo Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.8.4 Perrigo Main Business Overview
        11.8.5 Perrigo Latest Developments
    11.9 Boehringer Ingelheim
        11.9.1 Boehringer Ingelheim Company Information
        11.9.2 Boehringer Ingelheim Gastrointestinal Drugs Product Offered
        11.9.3 Boehringer Ingelheim Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.9.4 Boehringer Ingelheim Main Business Overview
        11.9.5 Boehringer Ingelheim Latest Developments
    11.10 Purdue Pharma
        11.10.1 Purdue Pharma Company Information
        11.10.2 Purdue Pharma Gastrointestinal Drugs Product Offered
        11.10.3 Purdue Pharma Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.10.4 Purdue Pharma Main Business Overview
        11.10.5 Purdue Pharma Latest Developments
    11.11 Dr. Falk Pharma GmbH
        11.11.1 Dr. Falk Pharma GmbH Company Information
        11.11.2 Dr. Falk Pharma GmbH Gastrointestinal Drugs Product Offered
        11.11.3 Dr. Falk Pharma GmbH Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.11.4 Dr. Falk Pharma GmbH Main Business Overview
        11.11.5 Dr. Falk Pharma GmbH Latest Developments
    11.12 Abbott
        11.12.1 Abbott Company Information
        11.12.2 Abbott Gastrointestinal Drugs Product Offered
        11.12.3 Abbott Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.12.4 Abbott Main Business Overview
        11.12.5 Abbott Latest Developments
    11.13 Jiangzhong
        11.13.1 Jiangzhong Company Information
        11.13.2 Jiangzhong Gastrointestinal Drugs Product Offered
        11.13.3 Jiangzhong Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.13.4 Jiangzhong Main Business Overview
        11.13.5 Jiangzhong Latest Developments
    11.14 Xian-Janssen
        11.14.1 Xian-Janssen Company Information
        11.14.2 Xian-Janssen Gastrointestinal Drugs Product Offered
        11.14.3 Xian-Janssen Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.14.4 Xian-Janssen Main Business Overview
        11.14.5 Xian-Janssen Latest Developments
    11.15 Takeda Pharmaceutical
        11.15.1 Takeda Pharmaceutical Company Information
        11.15.2 Takeda Pharmaceutical Gastrointestinal Drugs Product Offered
        11.15.3 Takeda Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.15.4 Takeda Pharmaceutical Main Business Overview
        11.15.5 Takeda Pharmaceutical Latest Developments
    11.16 AbbVie
        11.16.1 AbbVie Company Information
        11.16.2 AbbVie Gastrointestinal Drugs Product Offered
        11.16.3 AbbVie Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.16.4 AbbVie Main Business Overview
        11.16.5 AbbVie Latest Developments
    11.17 Eli Lilly and Company
        11.17.1 Eli Lilly and Company Company Information
        11.17.2 Eli Lilly and Company Gastrointestinal Drugs Product Offered
        11.17.3 Eli Lilly and Company Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.17.4 Eli Lilly and Company Main Business Overview
        11.17.5 Eli Lilly and Company Latest Developments
    11.18 Johnson & Johnson
        11.18.1 Johnson & Johnson Company Information
        11.18.2 Johnson & Johnson Gastrointestinal Drugs Product Offered
        11.18.3 Johnson & Johnson Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.18.4 Johnson & Johnson Main Business Overview
        11.18.5 Johnson & Johnson Latest Developments
    11.19 Bristol Myers Squibb
        11.19.1 Bristol Myers Squibb Company Information
        11.19.2 Bristol Myers Squibb Gastrointestinal Drugs Product Offered
        11.19.3 Bristol Myers Squibb Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.19.4 Bristol Myers Squibb Main Business Overview
        11.19.5 Bristol Myers Squibb Latest Developments
    11.20 Bausch Health
        11.20.1 Bausch Health Company Information
        11.20.2 Bausch Health Gastrointestinal Drugs Product Offered
        11.20.3 Bausch Health Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.20.4 Bausch Health Main Business Overview
        11.20.5 Bausch Health Latest Developments
    11.21 Livzon Pharmaceutical
        11.21.1 Livzon Pharmaceutical Company Information
        11.21.2 Livzon Pharmaceutical Gastrointestinal Drugs Product Offered
        11.21.3 Livzon Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.21.4 Livzon Pharmaceutical Main Business Overview
        11.21.5 Livzon Pharmaceutical Latest Developments
    11.22 Shandong Luoxin Pharmaceutical
        11.22.1 Shandong Luoxin Pharmaceutical Company Information
        11.22.2 Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Product Offered
        11.22.3 Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.22.4 Shandong Luoxin Pharmaceutical Main Business Overview
        11.22.5 Shandong Luoxin Pharmaceutical Latest Developments
    11.23 Gilead Sciences
        11.23.1 Gilead Sciences Company Information
        11.23.2 Gilead Sciences Gastrointestinal Drugs Product Offered
        11.23.3 Gilead Sciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.23.4 Gilead Sciences Main Business Overview
        11.23.5 Gilead Sciences Latest Developments
    11.24 Zhengdatianqing
        11.24.1 Zhengdatianqing Company Information
        11.24.2 Zhengdatianqing Gastrointestinal Drugs Product Offered
        11.24.3 Zhengdatianqing Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.24.4 Zhengdatianqing Main Business Overview
        11.24.5 Zhengdatianqing Latest Developments
    11.25 Zydus Lifesciences
        11.25.1 Zydus Lifesciences Company Information
        11.25.2 Zydus Lifesciences Gastrointestinal Drugs Product Offered
        11.25.3 Zydus Lifesciences Gastrointestinal Drugs Revenue, Gross Margin and Market Share (2021-2026)
        11.25.4 Zydus Lifesciences Main Business Overview
        11.25.5 Zydus Lifesciences Latest Developments

12 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Gastrointestinal Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
 Table 2. Gastrointestinal Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
 Table 3. Major Players of Acid-Related Disorder Drugs
 Table 4. Major Players of Inflammatory Bowel Disease Drugs
 Table 5. Major Players of Irritable Bowel Syndrome Drugs
 Table 6. Major Players of Constipation Drugs
 Table 7. Major Players of Diarrhea Drugs
 Table 8. Major Players of Gastrointestinal Motility Disorder Drugs
 Table 9. Major Players of Other Gastrointestinal Drugs
 Table 10. Gastrointestinal Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
 Table 11. Global Gastrointestinal Drugs Market Size by Type (2021-2026) & ($ millions)
 Table 12. Global Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
 Table 13. Major Players of Oral Solid Preparations
 Table 14. Major Players of Oral Liquid and Suspension Preparations
 Table 15. Major Players of Injectable Preparations
 Table 16. Major Players of Rectal Preparations
 Table 17. Major Players of Other Preparations
 Table 18. Gastrointestinal Drugs Market Size CAGR by Primary Dosage (2021 VS 2025 VS 2032) & ($ millions)
 Table 19. Global Gastrointestinal Drugs Market Size by Primary Dosage (2021-2026) & ($ millions)
 Table 20. Global Gastrointestinal Drugs Market Size Market Share by Primary Dosage (2021-2026)
 Table 21. Major Players of Small Molecule Drugs
 Table 22. Major Players of Biologic Drugs
 Table 23. Gastrointestinal Drugs Market Size CAGR by Drug Molecule (2021 VS 2025 VS 2032) & ($ millions)
 Table 24. Global Gastrointestinal Drugs Market Size by Drug Molecule (2021-2026) & ($ millions)
 Table 25. Global Gastrointestinal Drugs Market Size Market Share by Drug Molecule (2021-2026)
 Table 26. Gastrointestinal Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
 Table 27. Global Gastrointestinal Drugs Market Size by Application (2021-2026) & ($ millions)
 Table 28. Global Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)
 Table 29. Global Gastrointestinal Drugs Revenue by Player (2021-2026) & ($ millions)
 Table 30. Global Gastrointestinal Drugs Revenue Market Share by Player (2021-2026)
 Table 31. Gastrointestinal Drugs Key Players Head office and Products Offered
 Table 32. Gastrointestinal Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
 Table 33. New Products and Potential Entrants
 Table 34. Mergers & Acquisitions, Expansion
 Table 35. Global Gastrointestinal Drugs Market Size by Region (2021-2026) & ($ millions)
 Table 36. Global Gastrointestinal Drugs Market Size Market Share by Region (2021-2026)
 Table 37. Global Gastrointestinal Drugs Revenue by Country/Region (2021-2026) & ($ millions)
 Table 38. Global Gastrointestinal Drugs Revenue Market Share by Country/Region (2021-2026)
 Table 39. Americas Gastrointestinal Drugs Market Size by Country (2021-2026) & ($ millions)
 Table 40. Americas Gastrointestinal Drugs Market Size Market Share by Country (2021-2026)
 Table 41. Americas Gastrointestinal Drugs Market Size by Type (2021-2026) & ($ millions)
 Table 42. Americas Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
 Table 43. Americas Gastrointestinal Drugs Market Size by Application (2021-2026) & ($ millions)
 Table 44. Americas Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)
 Table 45. APAC Gastrointestinal Drugs Market Size by Region (2021-2026) & ($ millions)
 Table 46. APAC Gastrointestinal Drugs Market Size Market Share by Region (2021-2026)
 Table 47. APAC Gastrointestinal Drugs Market Size by Type (2021-2026) & ($ millions)
 Table 48. APAC Gastrointestinal Drugs Market Size by Application (2021-2026) & ($ millions)
 Table 49. Europe Gastrointestinal Drugs Market Size by Country (2021-2026) & ($ millions)
 Table 50. Europe Gastrointestinal Drugs Market Size Market Share by Country (2021-2026)
 Table 51. Europe Gastrointestinal Drugs Market Size by Type (2021-2026) & ($ millions)
 Table 52. Europe Gastrointestinal Drugs Market Size by Application (2021-2026) & ($ millions)
 Table 53. Middle East & Africa Gastrointestinal Drugs Market Size by Region (2021-2026) & ($ millions)
 Table 54. Middle East & Africa Gastrointestinal Drugs Market Size by Type (2021-2026) & ($ millions)
 Table 55. Middle East & Africa Gastrointestinal Drugs Market Size by Application (2021-2026) & ($ millions)
 Table 56. Key Market Drivers & Growth Opportunities of Gastrointestinal Drugs
 Table 57. Key Market Challenges & Risks of Gastrointestinal Drugs
 Table 58. Key Industry Trends of Gastrointestinal Drugs
 Table 59. Global Gastrointestinal Drugs Market Size Forecast by Region (2027-2032) & ($ millions)
 Table 60. Global Gastrointestinal Drugs Market Size Market Share Forecast by Region (2027-2032)
 Table 61. Global Gastrointestinal Drugs Market Size Forecast by Type (2027-2032) & ($ millions)
 Table 62. Global Gastrointestinal Drugs Market Size Forecast by Application (2027-2032) & ($ millions)
 Table 63. AstraZeneca Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 64. AstraZeneca Gastrointestinal Drugs Product Offered
 Table 65. AstraZeneca Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 66. AstraZeneca Main Business
 Table 67. AstraZeneca Latest Developments
 Table 68. Sanofi Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 69. Sanofi Gastrointestinal Drugs Product Offered
 Table 70. Sanofi Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 71. Sanofi Main Business
 Table 72. Sanofi Latest Developments
 Table 73. Bayer Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 74. Bayer Gastrointestinal Drugs Product Offered
 Table 75. Bayer Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 76. Bayer Main Business
 Table 77. Bayer Latest Developments
 Table 78. Pfizer Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 79. Pfizer Gastrointestinal Drugs Product Offered
 Table 80. Pfizer Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 81. Pfizer Main Business
 Table 82. Pfizer Latest Developments
 Table 83. GlaxoSmithKline Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 84. GlaxoSmithKline Gastrointestinal Drugs Product Offered
 Table 85. GlaxoSmithKline Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 86. GlaxoSmithKline Main Business
 Table 87. GlaxoSmithKline Latest Developments
 Table 88. Teva Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 89. Teva Gastrointestinal Drugs Product Offered
 Table 90. Teva Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 91. Teva Main Business
 Table 92. Teva Latest Developments
 Table 93. Ferring Pharmaceuticals Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 94. Ferring Pharmaceuticals Gastrointestinal Drugs Product Offered
 Table 95. Ferring Pharmaceuticals Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 96. Ferring Pharmaceuticals Main Business
 Table 97. Ferring Pharmaceuticals Latest Developments
 Table 98. Perrigo Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 99. Perrigo Gastrointestinal Drugs Product Offered
 Table 100. Perrigo Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 101. Perrigo Main Business
 Table 102. Perrigo Latest Developments
 Table 103. Boehringer Ingelheim Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 104. Boehringer Ingelheim Gastrointestinal Drugs Product Offered
 Table 105. Boehringer Ingelheim Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 106. Boehringer Ingelheim Main Business
 Table 107. Boehringer Ingelheim Latest Developments
 Table 108. Purdue Pharma Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 109. Purdue Pharma Gastrointestinal Drugs Product Offered
 Table 110. Purdue Pharma Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 111. Purdue Pharma Main Business
 Table 112. Purdue Pharma Latest Developments
 Table 113. Dr. Falk Pharma GmbH Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 114. Dr. Falk Pharma GmbH Gastrointestinal Drugs Product Offered
 Table 115. Dr. Falk Pharma GmbH Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 116. Dr. Falk Pharma GmbH Main Business
 Table 117. Dr. Falk Pharma GmbH Latest Developments
 Table 118. Abbott Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 119. Abbott Gastrointestinal Drugs Product Offered
 Table 120. Abbott Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 121. Abbott Main Business
 Table 122. Abbott Latest Developments
 Table 123. Jiangzhong Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 124. Jiangzhong Gastrointestinal Drugs Product Offered
 Table 125. Jiangzhong Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 126. Jiangzhong Main Business
 Table 127. Jiangzhong Latest Developments
 Table 128. Xian-Janssen Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 129. Xian-Janssen Gastrointestinal Drugs Product Offered
 Table 130. Xian-Janssen Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 131. Xian-Janssen Main Business
 Table 132. Xian-Janssen Latest Developments
 Table 133. Takeda Pharmaceutical Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 134. Takeda Pharmaceutical Gastrointestinal Drugs Product Offered
 Table 135. Takeda Pharmaceutical Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 136. Takeda Pharmaceutical Main Business
 Table 137. Takeda Pharmaceutical Latest Developments
 Table 138. AbbVie Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 139. AbbVie Gastrointestinal Drugs Product Offered
 Table 140. AbbVie Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 141. AbbVie Main Business
 Table 142. AbbVie Latest Developments
 Table 143. Eli Lilly and Company Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 144. Eli Lilly and Company Gastrointestinal Drugs Product Offered
 Table 145. Eli Lilly and Company Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 146. Eli Lilly and Company Main Business
 Table 147. Eli Lilly and Company Latest Developments
 Table 148. Johnson & Johnson Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 149. Johnson & Johnson Gastrointestinal Drugs Product Offered
 Table 150. Johnson & Johnson Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 151. Johnson & Johnson Main Business
 Table 152. Johnson & Johnson Latest Developments
 Table 153. Bristol Myers Squibb Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 154. Bristol Myers Squibb Gastrointestinal Drugs Product Offered
 Table 155. Bristol Myers Squibb Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 156. Bristol Myers Squibb Main Business
 Table 157. Bristol Myers Squibb Latest Developments
 Table 158. Bausch Health Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 159. Bausch Health Gastrointestinal Drugs Product Offered
 Table 160. Bausch Health Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 161. Bausch Health Main Business
 Table 162. Bausch Health Latest Developments
 Table 163. Livzon Pharmaceutical Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 164. Livzon Pharmaceutical Gastrointestinal Drugs Product Offered
 Table 165. Livzon Pharmaceutical Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 166. Livzon Pharmaceutical Main Business
 Table 167. Livzon Pharmaceutical Latest Developments
 Table 168. Shandong Luoxin Pharmaceutical Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 169. Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Product Offered
 Table 170. Shandong Luoxin Pharmaceutical Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 171. Shandong Luoxin Pharmaceutical Main Business
 Table 172. Shandong Luoxin Pharmaceutical Latest Developments
 Table 173. Gilead Sciences Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 174. Gilead Sciences Gastrointestinal Drugs Product Offered
 Table 175. Gilead Sciences Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 176. Gilead Sciences Main Business
 Table 177. Gilead Sciences Latest Developments
 Table 178. Zhengdatianqing Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 179. Zhengdatianqing Gastrointestinal Drugs Product Offered
 Table 180. Zhengdatianqing Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 181. Zhengdatianqing Main Business
 Table 182. Zhengdatianqing Latest Developments
 Table 183. Zydus Lifesciences Details, Company Type, Gastrointestinal Drugs Area Served and Its Competitors
 Table 184. Zydus Lifesciences Gastrointestinal Drugs Product Offered
 Table 185. Zydus Lifesciences Gastrointestinal Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
 Table 186. Zydus Lifesciences Main Business
 Table 187. Zydus Lifesciences Latest Developments


List of Figures
 Figure 1. Gastrointestinal Drugs Report Years Considered
 Figure 2. Research Objectives
 Figure 3. Research Methodology
 Figure 4. Research Process and Data Source
 Figure 5. Global Gastrointestinal Drugs Market Size Growth Rate (2021-2032) ($ millions)
 Figure 6. Gastrointestinal Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
 Figure 7. Gastrointestinal Drugs Sales Market Share by Country/Region (2025)
 Figure 8. Gastrointestinal Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
 Figure 9. Global Gastrointestinal Drugs Market Size Market Share by Type in 2025
 Figure 10. Global Gastrointestinal Drugs Market Size Market Share by Primary Dosage in 2025
 Figure 11. Global Gastrointestinal Drugs Market Size Market Share by Drug Molecule in 2025
 Figure 12. Gastrointestinal Drugs in Inflammatory Bowel Disease
 Figure 13. Global Gastrointestinal Drugs Market: Inflammatory Bowel Disease (2021-2026) & ($ millions)
 Figure 14. Gastrointestinal Drugs in IBS Disease
 Figure 15. Global Gastrointestinal Drugs Market: IBS Disease (2021-2026) & ($ millions)
 Figure 16. Gastrointestinal Drugs in Peptic Ulcer
 Figure 17. Global Gastrointestinal Drugs Market: Peptic Ulcer (2021-2026) & ($ millions)
 Figure 18. Gastrointestinal Drugs in GERD
 Figure 19. Global Gastrointestinal Drugs Market: GERD (2021-2026) & ($ millions)
 Figure 20. Gastrointestinal Drugs in Other
 Figure 21. Global Gastrointestinal Drugs Market: Other (2021-2026) & ($ millions)
 Figure 22. Global Gastrointestinal Drugs Market Size Market Share by Application in 2025
 Figure 23. Global Gastrointestinal Drugs Revenue Market Share by Player in 2025
 Figure 24. Global Gastrointestinal Drugs Market Size Market Share by Region (2021-2026)
 Figure 25. Americas Gastrointestinal Drugs Market Size 2021-2026 ($ millions)
 Figure 26. APAC Gastrointestinal Drugs Market Size 2021-2026 ($ millions)
 Figure 27. Europe Gastrointestinal Drugs Market Size 2021-2026 ($ millions)
 Figure 28. Middle East & Africa Gastrointestinal Drugs Market Size 2021-2026 ($ millions)
 Figure 29. Americas Gastrointestinal Drugs Value Market Share by Country in 2025
 Figure 30. United States Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 31. Canada Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 32. Mexico Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 33. Brazil Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 34. APAC Gastrointestinal Drugs Market Size Market Share by Region in 2025
 Figure 35. APAC Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
 Figure 36. APAC Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)
 Figure 37. China Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 38. Japan Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 39. South Korea Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 40. Southeast Asia Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 41. India Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 42. Australia Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 43. Europe Gastrointestinal Drugs Market Size Market Share by Country in 2025
 Figure 44. Europe Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
 Figure 45. Europe Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)
 Figure 46. Germany Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 47. France Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 48. UK Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 49. Italy Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 50. Russia Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 51. Middle East & Africa Gastrointestinal Drugs Market Size Market Share by Region (2021-2026)
 Figure 52. Middle East & Africa Gastrointestinal Drugs Market Size Market Share by Type (2021-2026)
 Figure 53. Middle East & Africa Gastrointestinal Drugs Market Size Market Share by Application (2021-2026)
 Figure 54. Egypt Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 55. South Africa Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 56. Israel Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 57. Turkey Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 58. GCC Countries Gastrointestinal Drugs Market Size Growth 2021-2026 ($ millions)
 Figure 59. Americas Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 60. APAC Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 61. Europe Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 62. Middle East & Africa Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 63. United States Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 64. Canada Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 65. Mexico Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 66. Brazil Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 67. China Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 68. Japan Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 69. Korea Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 70. Southeast Asia Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 71. India Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 72. Australia Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 73. Germany Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 74. France Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 75. UK Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 76. Italy Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 77. Russia Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 78. Egypt Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 79. South Africa Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 80. Israel Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 81. Turkey Gastrointestinal Drugs Market Size 2027-2032 ($ millions)
 Figure 82. Global Gastrointestinal Drugs Market Size Market Share Forecast by Type (2027-2032)
 Figure 83. Global Gastrointestinal Drugs Market Size Market Share Forecast by Application (2027-2032)
 Figure 84. GCC Countries Gastrointestinal Drugs Market Size 2027-2032 ($ millions)

Companies Mentioned

AstraZeneca

Sanofi

Bayer

Pfizer

GlaxoSmithKline

Teva

Ferring Pharmaceuticals

Perrigo

Boehringer Ingelheim

Purdue Pharma

Dr. Falk Pharma GmbH

Abbott

Jiangzhong

Xian-Janssen

Takeda Pharmaceutical

AbbVie

Eli Lilly and Company

Johnson & Johnson

Bristol Myers Squibb

Bausch Health

Livzon Pharmaceutical

Shandong Luoxin Pharmaceutical

Gilead Sciences

Zhengdatianqing

Zydus Lifesciences

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff